Rosen Law Firm Reminds Hemispherx Biopharma, Inc. Investors of Important February 22, 2013 Deadline -- HEB

Rosen Law Firm Reminds Hemispherx Biopharma, Inc. Investors of Important
February 22, 2013 Deadline -- HEB

NEW YORK, Feb. 1, 2013 (GLOBE NEWSWIRE) -- The Rosen Law Firm reminds
investors of the important February 22, 2013 lead plaintiff deadline in the
class action filed on behalf of investors who purchased the securities of
Hemispherx Biopharma, Inc., (NYSE:HEB) during the period from March 19, 2012
through December 17, 2012.

To join the Hemispherx class action, visit the firm's website at
http://rosenlegal.com, or call Phillip Kim, Esq., toll-free, at 866-767-3653;
you may also email pkim@rosenlegal.com for information on the class action.

The Complaint asserts violations of the federal securities laws against
Hemispherx and its officers and directors for issuing false and misleading
information about its lead drug candidate Ampligen. Specifically, that
Hemispherx misstated the safety and efficacy of Ampligen, and touted
purportedly positive results from Ampligen's clinical trials.

On December 18, 2012, the FDA published a staff report concluding that the
Company's studies were "ill-defined and invalid" with signals of efficacy that
were inconsistent between clinical trials, and based on the limited quality of
the data, "it is difficult to draw conclusions regarding potential safety
signals," but the "review identified nine potential safety concerns associated
with Ampligen." The Complaint alleges that as a result of this adverse
information, Hemispherx stock price dropped and investors have been damaged.

If you wish to serve as lead plaintiff, you must move the Court no later than
February 22, 2013.  A lead plaintiff is a representative party acting on
behalf of other class members in directing the litigation. If you wish to join
the litigation, or to discuss your rights or interests regarding this class
action, please contact Phillip Kim, Esq. of The Rosen Law Firm, toll-free, at
866-767-3653, or via e-mail at pkim@rosenlegal.com. You may also visit the
firm's website at http://www.rosenlegal.com.

The Rosen Law Firm represents investors throughout the globe, concentrating
its practice in securities class actions and shareholder derivative
litigation.

Attorney advertising. Prior results do not guarantee a similar outcome.

CONTACT: Laurence Rosen, Esq.
         Phillip Kim, Esq.
         The Rosen Law Firm P.A.
         275 Madison Avenue 34th Floor
         New York, New York 10016
         Tel:  (212) 686-1060
         Weekends Tel: (917) 562-8616
         Toll Free: 1-866-767-3653
         Fax: (212) 202-3827
         lrosen@rosenlegal.com
         pkim@rosenlegal.com
         szhang@rosenlegal.com
         www.rosenlegal.com